153Sm-Lexidronam pentasodium (153Sm-EDTMP – Quadramet®) is a therapeutic agent used for the relief of bone pain in patients with multiple osteoblastic skeletal metastases which take up 99mTc-biphosphonate on bone scan. The US MA was originally obtained in March 1997.
153Sm-Lexidronam is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. Doses are on average 1.0 mCi/kg.
Leading Emitter: beta electrons (β–)